Stay updated with breaking news from Nasdaq nbix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $154.00 to $164.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 17.29% from […] ....
Yousif Capital Management LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,808 shares of the company’s stock after selling 370 shares during the quarter. Yousif Capital Management LLC’s […] ....
New York State Common Retirement Fund lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% during the 4th quarter, Holdings Channel reports. The firm owned 214,396 shares of the company’s stock after selling 29,456 shares during the quarter. New York State Common Retirement Fund’s holdings in Neurocrine Biosciences were worth $28,249,000 […] ....
New York State Common Retirement Fund lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 214,396 shares of the company’s stock after selling 29,456 shares during the period. New York State Common […] ....
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports. Other equities research analysts have also issued research reports about the company. Wells Fargo & Company upped their target price on Neurocrine Biosciences from $127.00 to […] ....